Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting

Bijal ShahMei XueWesley FurnbackKeri Yang2026-03-222026-03-22202510.1080/14796694.2025.2554354https://doi.org/10.1080/14796694.2025.2554354https://andeanlibrary.org/handle/123456789/44061Citaciones: 2In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.enIbrutinibMedicineBruton's tyrosine kinaseMantle cell lymphomaOncologyInternal medicineTyrosine kinaseCancer researchLymphomaReal-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology settingarticle